ClinicalTrials.gg
CompletedNCT04580745Updated Aug 1, 2025

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

A Phase 1 interventional study of MORF-057 and Placebo for MORF-057 in Healthy Volunteers, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (part of Eli Lilly and Company) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • MORF-057
03

In context

Lead sponsor

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects between 18 to 65 years old with a between 18 and 32 kg/m2
  • Determined to be medically healthy by the Investigator.
  • Use of acceptable methods of .
  • Ability to provide written and to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • History of any , except basal or squamous cell carcinoma of the skin that resolved or in remission prior to Screening.
  • Abnormal laboratory values at Screening.
  • Any major diseases.
  • Female who is pregnant or breastfeeding, or planning to become pregnant during the course of the study.
  • Unwilling or unable to comply with the requirements of the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    MORF-057

    SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057. Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.

    Drug: MORF-057

  • Experimental
    Placebo for MORF-057

    SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.

    Drug: Placebo for MORF-057

Interventions

  • SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057. Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.

  • DrugPlacebo for MORF-057

    SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and safety signals observed during single and multiple ascending doses of MORF-057 administered orally to healthy adult subjects

    Subject incidence of adverse events and serious adverse events

    Time frame: Day -1 to Day 28

  2. Maximum Plasma Concentration (Cmax) of MORF-057 in a fed state

    Cmax (Food Effect cohort)

    Time frame: Day -1 to Day 28

  3. Time to Reach Cmax (Tmax) of MORF-057 in a fed state

    Tmax (Food Effect cohort)

    Time frame: Day -1 to Day 28

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) during single and multiple ascending doses of MORF-057

    Cmax of MORF-057

    Time frame: Day -1 to Day 28

  2. Time to Reach Cmax (Tmax) during single and multiple ascending doses of MORF-057

    Tmax of MORF-057

    Time frame: Day -1 to Day 28

  3. Incidence of adverse events and safety signals observed during single dose of MORF-057 administered after a meal to healthy subjects.

    Subject incidence of adverse events and serious adverse events.

    Time frame: Day -1 to Day 28

07

Study locations

1 site
  • Medpace
    Cincinnati, Ohio 45227, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Mar 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Oct 8, 2020
StartActual
Sep 23, 2020
Primary completionActual
Mar 31, 2021
CompletionActual
Apr 12, 2021
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04580745
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Sep 23, 2020
Primary completion
Mar 31, 2021
Completion
Apr 12, 2021
Last update
Aug 1, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MORF-057

Start the discussion